抗凝药物治疗患者中按药物类别划分的异常子宫出血:结局与管理
该回顾性病历审查纳入2015年1月至2020年1月城市医院网络中18至55岁接受治疗性抗凝的2479例女性,645例发生异常子宫出血;
要点
- 2479例治疗性抗凝女性中645例发生异常子宫出血。
核心结论
- 治疗性抗凝患者中异常子宫出血频繁发生。
- 本样本中异常子宫出血发生率因抗凝药类别和种族不同而差异较大;单用直接口服抗凝药风险最低。
- 出血相关急诊就诊、输血和妇科操作等重要后遗症常见。
- 平衡治疗性抗凝患者的出血与凝血风险需要细致的方法,并应涉及血液科医生与妇科医生的协作管理。
研究设计与样本
- 经机构审查委员会豁免的回顾性病历审查。
- 纳入2015年1月至2020年1月城市医院网络中18至55岁、处方治疗性抗凝药(包括维生素K拮抗剂、低分子量肝素和直接口服抗凝药)的女性患者。
- 排除既往有异常子宫出血及绝经患者。
- 采用Pearson卡方检验和方差分析评估异常子宫出血、抗凝药类别与其他协变量的关联。
- 主要结局(按抗凝药类别的异常子宫出血比值比)采用逻辑回归建模,多变量模型纳入年龄、抗血小板治疗、体重指数和种族。
主要发现
- 符合纳入标准的2479例患者中,645例在启动治疗性抗凝后诊断为异常子宫出血。
- 非白人种族与异常子宫出血较高比值比相关,较低年龄亦相关。
- 异常子宫出血患者最常用的激素治疗为左炔诺孕酮宫内节育器(7.6%;49/645)和口服孕激素(7.6%;49/645)。
关键数值与推荐
- 68例(10.5%;68/645)因异常子宫出血急诊就诊;190例(29.5%;190/645)接受输血;79例(12.2%;79/645)开始任何出血药物治疗;121例(18.8%;121/645)接受任何妇科操作。
临床怎么用
- 作者认为平衡治疗性抗凝患者的出血与凝血风险需要细致的方法,并应涉及血液科医生与妇科医生的协作管理。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Although abnormal uterine bleeding is a known adverse effect of anticoagulant drugs, true rates have not been widely studied. Society-backed recommendations and guidelines do not yet exist for prevention and management of abnormal uterine bleeding among anticoagulated patients. OBJECTIVE: This study aimed to describe the incidence of new-onset abnormal uterine bleeding among patients receiving therapeutic anticoagulation by anticoagulant class, and to evaluate gynecologic treatment patterns. STUDY DESIGN: We conducted an institutional review board-waived retrospective chart review of female patients aged 18 to 55 years and prescribed therapeutic anticoagulants, including vitamin-K antagonists, low-molecular-weight heparins, and direct oral anticoagulants, in an urban hospital network from January 2015 through January 2020. We excluded patients with antecedent abnormal uterine bleeding and menopause. Associations between abnormal uterine bleeding, anticoagulant class, and other covariates were evaluated with Pearson chi-square and analysis-of-variance tests. The primary outcome, abnormal uterine bleeding odds by anticoagulant class, was modeled with logistic regression. Age, antiplatelet therapy, body mass index, and race were included in our multivariable model. Secondary outcomes included emergency department visits and treatment patterns. RESULTS: Of the 2479 patients who met the inclusion criteria, 645 were diagnosed with abnormal uterine bleeding after initiating therapeutic anticoagulation. After adjusting for age, race, body mass index, and concurrent use of antiplatelet therapy, those receiving all 3 classes of anticoagulants had higher odds of experiencing abnormal uterine bleeding (adjusted odds ratio, 2.63; confidence interval, 1.70-4.08; P<.001), whereas those taking only direct oral anticoagulants had the lowest odds (adjusted odds ratio, 0.70; confidence interval, 0.51-0.97; P=.032), with vitamin-K antagonists as the reference group. Race other than White was associated with higher odds of abnormal uterine bleeding, as was lower age. The most common hormone therapies used among patients with abnormal uterine bleeding were levonorgestrel intrauterine devices (7.6%; 49/645) and oral progestins (7.6%; 49/645). Sixty-eight patients (10.5%; 68/645) had an emergency department visit for abnormal uterine bleeding; 29.5% (190/645) of patients received a blood transfusion; 12.2% (79/645) began any pharmacologic therapy for bleeding; and 18.8% (121/645) underwent any gynecologic procedure. CONCLUSION: Abnormal uterine bleeding occurs frequently among patients on therapeutic anticoagulation. Incidence in this sample varied considerably by anticoagulant class and race; use of single-agent direct oral anticoagulation carried the lowest risk. Important sequelae such as bleeding-related emergency department visits, blood transfusions, and gynecologic procedures were common. Balancing bleeding and clotting risk in patients on therapeutic anticoagulation requires a nuanced approach and should involve collaborative management between hematologists and gynecologists.
引用
- Brioso XB, Bolt M, Sammel MD, et al. Abnormal uterine bleeding in anticoagulated patients by drug class: outcomes and management. Am J Obstet Gynecol. 2023. PMID: 37201695. doi:10.1016/j.ajog.2023.05.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。